Market Place
Sourcing Support
PANTHERx® Rare Selected by UCB as the Exclusive Specialty Pharmacy for ZILBRYSQ
10 Jan 2024 //
PR NEWSWIRE
ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S
03 Jan 2024 //
PR NEWSWIRE
UCB announces U.S. FDA approval of ZILBRYSQ for myasthenia gravis
17 Oct 2023 //
PR NEWSWIRE
UCB announces FDA acceptance of NDA and EMA MAA validation for zilucoplan
14 Nov 2022 //
PRNEWSWIRE
UCB details positive pivotal data for myasthenia gravis
10 May 2022 //
ENDPTS
Innovative Medicine designation for self-administered treatment of rare disease
17 Feb 2022 //
PHARMAFILE
UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study
04 Feb 2022 //
PRNEWSWIRE
UK hospitals to trial five new drugs in search for coronavirus treatment
02 Jun 2020 //
THEGUARDIAN
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG
18 Feb 2020 //
BUSINESSWIRE
UCB Agrees to Acquire Ra Pharmaceuticals: To Improve Treatment Options
10 Oct 2019 //
BUSINESSWIRE
Ra Pharma Receives Orphan Drug Designation from the U.S. FDA for Zilucoplan
03 Sep 2019 //
BUSINESSWIRE
Ra Pharmaceuticals Announces Completion of End-of-Phase 2 Interactions
09 Apr 2019 //
BUSINESSWIRE
Ra Pharmaceuticals Receives Milestone Payment Under Agreement with Merck
08 Dec 2018 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.